RecruitingNot ApplicableNCT05066178
Speech Treatment for Minimally Verbal Children With ASD and CAS
Sponsor
MGH Institute of Health Professions
Enrollment
20 participants
Start Date
May 1, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
Comorbid Childhood Apraxia of Speech (CAS) may be one factor that limits speech development in some minimally verbal children with autism. CAS is a disorder affecting speech movement planning. This study tests whether CAS-specific treatment, appropriately modified for minimally verbal children with autism, improves their speech.
Eligibility
Min Age: 5 YearsMax Age: 18 Years
Inclusion Criteria4
- Meets criteria for Autism Spectrum Disorder
- Able to correctly repeat at least 2 syllables
- Meets criteria for Childhood Apraxia of Speech
- Lives in an environment where child is exposed to English at least 50% of the time
Exclusion Criteria4
- Poorly controlled seizures
- Factors such as blindness or deafness that contribute to minimally verbal status
- Lives in an environment where English is not spoken at least 50% of the time
- Child experiences behavioral challenges that preclude participation in the study
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
BEHAVIORALCAS Treatment for Minimally Verbal Children with Autism
Treatment involves principles of motor learning embedded in a naturalistic developmental milieu
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05066178
Related Trials
Behavior Analytic Support of Needle-related Hospital Visits for Autistic Patients
NCT067127841 location
Propranolol for Aggression, Self-Injury, and Severe Disruptive Behavior in Adolescents and Adults With Autism
NCT070912792 locations
Pimavanserin for Rigid-compulsive Symptoms in Autism Spectrum Disorder
NCT059992402 locations
Combined Effects of Sensorimotor Integration and Post-facilitation Stretch in Autism Spectrum Disorder
NCT074843471 location
Alpha Auditory Entrainment for Cognitive Enhancement and Sensory Hypersensitivity in Youth With Developmental Disorders
NCT062277801 location